In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
Amid an ongoing epidemic of opioid abuse in the USA, the country’s medicines regulator has announced safety label changes for opioids aimed at ensuring their safe use. 14 April 2023
Pharmaceutical
The USA’s Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness and value of Madrigal Pharmaceuticals resmetirom and Intercept Pharmaceuticals’ obeticholic acid (OCA) for non-alcoholic steatohepatitis (NASH). 14 April 2023
Pharmaceutical
An Expert View from Nicki Pow, head of delivery (digital and design), ramarketing. 13 April 2023
Biosimilars
A lot of topics were discussed at the 2023 China innovative medicine (device) medical conference (CMAC) held in Suzhou on April 7. Among them were real world studies, medical affairs and how to use AI to speed up discoveries. But one most talked about was the challenges for Chinese biotechs to go global. 13 April 2023
Biotechnology
Sino-American biotech BeiGene today announced the first major step in the company’s expansion in Latin America (LATAM) with the formal opening of its office in São Paulo, Brazil. 13 April 2023
Biotechnology
New York-based Tiziana Life Sciences, a biotech company developing breakthrough immunomodulation therapies via novel routes of drug delivery, has revealed plans to investigate intranasal foralumab for the treatment of long COVID. 13 April 2023
Biotechnology
A draft evidence report from Boston, USA-based watchdog The Institute for Clinical and Economic Review (ICER) suggests a cost-effective price of up to $1.9 million for new sickle cell disease (SCD) therapies. 13 April 2023
Biotechnology
Data from UCB’s Phase III studies of rozanolixizumab and zilucoplan in generalized myasthenia gravis (gMG) have been published in The Lancet Neurology. 13 April 2023
Pharmaceutical
News that the US regulator is to pause enrollment in a key trial of evobrutinib has hit shares of developer Merck KGaA. 13 April 2023
Biotechnology
Basel, Switzerland-based Alentis Therapeutics today announced a $105 million in Series C financing. 13 April 2023
Biotechnology
US clinical-stage oncology biotech Cybrexa Therapeutics has appointed Jaya Gautam as senior vice president, technical operations. 13 April 2023
Pharmaceutical
The US Biotechnology Innovation Organization (BIO) has signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to the ‘morning after’ abortion pill mifepristone (marketed under the trade name Mifeprex) that would create regulatory barriers and potentially upend the US Food and Drug Administration’s (FDA) authority to approve life-saving and life-enhancing therapies to patients. 13 April 2023
Pharmaceutical
US medicines cost watchdog the Institute for Clinical and Economic Review (ICER) has posted a Protocol outlining how it will conduct its third annual assessment of how well major insurers’ prescription drug coverage policies align with a set of fair access standards. 13 April 2023
Biotechnology
US biotech major Biogen today announced that it has exercised its option to license Denali Therapeutic’s antibody transport vehicle (ATV): Amyloid beta program (ATV:Aβ), lifting the latter’s shares up 3% in early trading. 12 April 2023
Biotechnology
The protocol for the POSITIVE study, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint, has been published in the British Medical Journal. 12 April 2023
Biotechnology
As part of its aim to expand into cell therapies, Danish diabetes care giant Novo Nordisk has entered into a collaboration with a Canadian biotech that could cost it as much as $2.6 billion. 12 April 2023
Pharmaceutical
A US program worth at least $5 billion is on its way to power development of new COVID-19 vaccines and treatments. 12 April 2023
Biotechnology
South Korean biotech Genexine saw its shares gain more than 9% to 13,850 won, after, along with partner KG Bio, it released interim results of the Phase III clinical trial of GX-E4 (efepoetin alfa), a candidate for chronic kidney disease (CKD)-induced anemia. 12 April 2023
Biotechnology
Japan’s largest drugmaker Takeda has linked up with little-known Canadian biotech Treventis for the further research, development, and commercialization of small molecules that target tau, a key protein in Alzheimer’s disease (AD). 12 April 2023
Biotechnology
Concerns about Moderna’s post-COVID strategy have sparked a share price slide, following an ambivalent analysis from the firm’s flu vaccine program. 12 April 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze